Matthias von Herrath
Overview
Explore the profile of Matthias von Herrath including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
128
Citations
2834
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ling E, Lemos J, Hirani K, von Herrath M
Diabetol Int
. 2024 Oct;
15(4):761-776.
PMID: 39469552
Type 1 diabetes (T1D) is characterized by the progressive destruction of insulin-producing beta cells in the pancreas. Despite improvements in insulin monitoring techniques, there remains no cure for T1D. Individuals...
2.
Teixeira P, Battelino T, Carlsson A, Gudbjornsdottir S, Hannelius U, von Herrath M, et al.
Diabetologia
. 2024 Feb;
67(6):985-994.
PMID: 38353727
The type 1 diabetes community is coalescing around the benefits and advantages of early screening for disease risk. To be accepted by healthcare providers, regulatory authorities and payers, screening programmes...
3.
Lemos J, Hirani K, von Herrath M
Front Immunol
. 2024 Jan;
14:1326711.
PMID: 38239343
Type 1 diabetes (T1D) is caused by an autoimmune process which culminates in the destruction of insulin-producing beta cells in the pancreas. It is widely believed that a complex and...
4.
Pfeiffer S, Quesada-Masachs E, McArdle S, Zilberman S, Yesildag B, Mikulski Z, et al.
Clin Immunol
. 2022 Jul;
241:109076.
PMID: 35817292
We defined the effect of the anti-inflammatory cytokines IL4 and IL10 on an in vitro model of human T1D. After preincubation with IL4 or IL10, human islet microtissues were co-cultured...
5.
Wesley J, Pagni P, Bergholdt R, Kreiner F, von Herrath M
Curr Opin Endocrinol Diabetes Obes
. 2022 Jul;
29(4):379-385.
PMID: 35776831
Purpose Of Review: Dissect the field of antigen-specific immunotherapy (ASIT) in type 1 diabetes (T1D), highlighting the major barriers currently blocking clinical translation. Recent Findings: ASIT remains a promising approach...
6.
Kreiner F, Kraaijenhof J, von Herrath M, Hovingh G, von Scholten B
Expert Rev Clin Immunol
. 2022 Feb;
18(4):377-389.
PMID: 35212585
Introduction: Diabetes, chronic kidney disease (CKD) and cardiovascular disease (CVD) are cardiometabolic diseases that remain amongst the leading causes of morbidity and premature mortality. Here, we review the current understanding...
7.
Pagni P, Chaplin J, Wijaranakula M, Wesley J, Granger J, Cracraft J, et al.
Diabetes
. 2021 Dec;
PMID: 34957480
Type 1 diabetes is an autoimmune disease in which insulin-secreting β-cells are destroyed, leading to a life-long dependency on exogenous insulin. There are no approved disease-modifying therapies available, and future...
8.
Quesada-Masachs E, Zilberman S, Rajendran S, Chu T, McArdle S, Kiosses W, et al.
Diabetologia
. 2021 Dec;
65(2):387-401.
PMID: 34932134
Aims/hypothesis: We aimed to characterise and quantify the expression of HLA class II (HLA-II) in human pancreatic tissue sections and to analyse its induction in human islets. Methods: We immunostained...
9.
von Herrath M, Bonifacio E
Proc Natl Acad Sci U S A
. 2021 Oct;
118(44).
PMID: 34697240
No abstract available.
10.
Dejgaard T, von Scholten B, Christiansen E, Kreiner F, Bardtrum L, von Herrath M, et al.
Diabetes Obes Metab
. 2021 Aug;
23(12):2752-2762.
PMID: 34463425
Aim: To evaluate 26 weeks of liraglutide treatment in type 1 diabetes (T1D) by subgroups in the ADJUNCT ONE and ADJUNCT TWO trials. Materials And Methods: ADJUNCT ONE and ADJUNCT...